SICURANZA ANNA | Elenco docenti

Gozzetti, A., Pacelli, P., Caroni, F., Raspadori, D., Bestoso, E., Antonioli, E., et al. (2026). MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM. BRITISH JOURNAL OF HAEMATOLOGY [10.1111/bjh.70448]. - dettaglio
Pacini, E., Esposito Vangone, B., Santoni, A., Malchiodi, M., Zuanelli Brambilla, C., Sicuranza, A., et al. (2026). Impressive Skin and Systemic Response Despite Patient Underestimation and Delayed Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm. CASE REPORTS IN HEMATOLOGY, 2026(1) [10.1155/crh/4591883]. - dettaglio
Caggiano, V., Sbalchiero, J., Frassi, M., Martin-Nares, E., Hinojosa-Azaola, A., Sikora, M., et al. (2026). Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registries. FRONTIERS IN MEDICINE, 12 [10.3389/fmed.2025.1659758]. - dettaglio
Gavioli, F., Caggiano, V., Sbalchiero, J., Frassi, M., Crisafulli, F., Cavazzana, I., et al. (2026). VEXAS syndrome and cancer: Insights about a possible “Tip of the Iceberg”. Ambidirectional data from the international AIDA network registries. SEMINARS IN ARTHRITIS AND RHEUMATISM, 77 [10.1016/j.semarthrit.2026.152932]. - dettaglio
Sicuranza, A., Cavalleri, A., Bernardi, S. (2025). The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers. FRONTIERS IN ONCOLOGY, 15 [10.3389/fonc.2025.1546813]. - dettaglio

Tutte le pubblicazioni